Opposite roles of D1 and D5 dopamine receptors in locomotion revealed by selective antisense oligonucleotides

NeuroReport

Volumn 9, Issue 1, 1998, Pages 1-5

  Dziewczapolski, Gustavo ^a   Menalled, Liliana B ^a   García, María C ^a   Mora, Marcelo A ^a   Gershanik, Oscar S ^a   Rubinstein, Marcelo ^b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

6 OHDA lesioned rat; Antisense oligodeoxynucleotide; D1 dopamine receptor; D5 dopamine receptor; Locomotor activity

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTISENSE OLIGONUCLEOTIDE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; SULPIRIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING KINETICS; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCOMOTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RECEPTOR BINDING;

EID: 0032484630     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199801050-00001     Document Type: Article

References (25)

1. Waddington J. D1:D2 Dopamine Receptor Interactions. San Diego: Academic Press, 1993.
2. Tiberi M, Jarvie KR, Silvia C et al. Proc Natl Acad Sci USA 88, 7491-7495 (1991).
3. Meador-Woodruff JH, Mansour A, Grandy DK et al. Neurosci Lett 145, 209-212 (1992).
4. Bergson C, Mrzljak L, Smiley JF et al. J Neurosci 15, 7821-7836 (1995).
5. Xu M, Moratalia R, Gold LH et al. Cell 79, 729-742 (1994).
6. Calabresi P, Saiardi A, Pisani A et al. J Neurosci 17, 4536-4544 (1997).
7. Zhang SP, Zhou LW and Weiss B. J Pharmacol Exp Ther 271, 1462-1470 (1994).
8. Apostolakis EM, Garai J, Fox C et al. J Neurosci 16, 4823-4834 (1996).
9. Dziewczapolski G, Mora MA, Menalled LB et al. Naunyn-Schmiedeberg's Arch Pharmacol 355, 30-35 (1997).
10. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1986.
11. Ungerstedt U and Arbuthnott GW. Brain Res 24, 485-493 (1970).
12. Dziewczapolski G, Murer G, Agid Y et al. NeuroReport 8, 975-979 (1997).
13. Monsma FJ, Mahan LC, McVittie LD et al. Proc Natl Acad Sci USA 87, 6723-6727
14. Chritin M, Blanchard V, Raisman-Vozari R et al. Eur J Neurosci 8, 2511-2520 (1996).
15. Bouthenet ML, Martres MP, Sales N and Schwartz JC. Neuroscience 20, 117-155 (1987).
16. Arnt J and Hyttel J. Eur J Pharmacol 102, 349-354 (1984).
17. Waters N, Svensson K, Haadsma-Svensson SR et al. J Neural Transm 94, 11-19 (1993).
18. Damsma G, Tham CS, Robertson GS and Fibiger HC. Eur J Pharmacol 186, 335-338 (1990).
19. Féger J, Hassani O-K and Mouroux M. Movement Disord 12 (suppl 1), 93 (1997).
20. Wahlestedt C, Golanov E, Yamamoto S et al. Nature 363, 260-263 (1993).
21. Standaert DG, Testa CM, Rudolf GD et al. J Pharmacol Exp Ther 276, 342-352 (1996).
22. Zhou LW, Zhang SP, Qin ZH and Weiss B. J Pharmacol Exp Ther 268, 1015-1023 (1994).
23. Weiss B, Zhang SP and Zhou LW. Life Sci 60, 433-455 (1997).
24. Qin ZH, Zhou LW, Zhang SP et al. Mol Pharmacol 48, 730-737 (1995).
25. Wagner, RW. Nature 372, 333-335 (1994).